When the novel coronavirus epidemic started to hit Wuhan early last year, Jiangsu Kanion Pharmaceutical Co., Ltd. received an emergent message from Wuchang district government of Wuhan concerning the production of a TCM medicine developed by Tong Xiaolin, leader of the National TCM Medical Treatment Expert Team for Novel Coronary Pneumonia and Academician of the Chinese Academy of Sciences.
Among the Chinese medicinal preparations commissioned for production, the No. 1 prescription is very important and is the basis of prevention and control treatment.
Ordinary Chinese medicine decoction generally requires 8 to 12 medicinal materials but the No. 1 prescription requires 20 medicinal materials.
The need for more medicinal materials means a large number of prescriptions, which would pose new challenges to the production process.
To make a new Chinese medicine granule, you must find a suitable process route. Different ratios and methods mean different effects. This process usually takes several weeks.
Xu Dianhong and his team made repeated comparison and adjustment before finally settling on a stable process route for the making of the TCM granule.
Xu Dianhong, Director of Production Department, Jiangsu Kanion Pharmaceutical Co., Ltd.
1,100 employees in 6 preparation workshops used 48 extraction tanks to work around the clock, and sent to Wuhan the first batch of Chinese medicine granule for the prevention and treatment of novel coronary pneumonia within 48 hours.
In less than one week, Xu Dianhong and his team delivered 48,000 servings of traditional Chinese medicine granules for a period of 14 days.
Tong Xiaolin said that the TCM medicine greatly improved the quality of life of the COVID-19 patients, and none of the patients changed from mild symptoms to severe.
Xu Dianhong, Director of Production Department, Jiangsu Kanion Pharmaceutical Co., Ltd.
In recent years, Xu Dianhong and his team have solved the process problems of more than 10 soft capsule varieties, and also made outstanding contributions in energy conservation and consumption reduction, production and efficiency enhancement, process optimization, and quality stability.
Xu Dianhong, Director of Production Department, Jiangsu Kanion Pharmaceutical Co., Ltd.
